Cold-dependent activation of complement (CDAC) is a phenomenon characterized by low hemolytic complement activity in chilled serum. Complement component levels are normal when measured immunologically, and there is normal hemolytic activity in EDTA plasma or serum maintained at 37°C. Little attention has been paid to CDAC except in Japan, and current unfamiliarity with it, even by clinical immunologists, can lead to confusion and unnecessary laboratory tests. A 66-year-old patient with a complex medical history is described whose complement tests showed abnormalities characteristic of CDAC. Evidence for classical complement pathway activation in the cold was obtained by CHso measurements, by hemolytic C4 determinations, by C4a, C3a, and C4d generation, and by quantitating Clg-CI~-(C1 inhibitor)2 complexes. A good correlation was observed among these parameters. Cryoprecipitates were absent. CDAC activity has persisted for over 5 years and is greater at 13 than at 4°C. Activation is ablated by heating at 56°C and restored by the addition of C1 to the heated serum. Adsorption by streptococcal protein G-Sepharose and precipitation by 2.5% polyethylene glycol support the hypothesis that CDAC is caused by aggregated IgG. The CDAC factor(s) also induces complement activation in normal serum but has not interfered with Raji cell or Clq binding tests or with FACS analysis. More limited studies of a second individual experiencing CDAC yielded similar results.
INTRODUCTION
Discrepancies between hemolytic complement activity in serum versus plasma have been reported in abstracts published beginning in 1970 (1) (2) (3) (4) . Although the initial emphasis was on the possible role of blood coagulation factors (I-3, 5), it was subsequently discovered that the serum abnormality was associated with cooling the serum in vitro (4, (6) (7) (8) (9) (10) (11) (12) (13) (14) . The usual features of cold-dependent activation of complement (CDAC) include low CHs0, low hemolytic C4, and normal hemolytic C5-C9 in chilled serum, whereas these values are nearly normal in EDTA plasma and in serum kept at 37°C. In addition, immunologic measurements of complement components are normal even in chilled serum. C1 inhibitor (C1 INH) levels also are normal, and precipitating cryoglobulins and cryofibrinogens are absent. Although there have been unreported cases, apparently only 11 patients with CDAC have been reported in the United States (1) (2) (3) (4) 10) . In contrast, more than 40 such individuals have been described by Japanese investigators (5) (6) (7) (8) (9) (11) (12) (13) . Many of these patients had chronic liver disease, and 5 of 574 patients with primary renal disease had CDAC (9) . In addition, Akasaki et al. (9) found evidence of CDAC in 5 of 8100 apparently healthy Japanese.
CASE REPORTS

Patient i
Patient 1 was a 66-year-old woman who was initially seen by us in 1985 because of swelling and burning of the tongue. The complex medical history included hyperparathyroidism with resection of a parathyroid adenoma, thyroid nodule resection, splenectomy for splenic artery aneurysm, border- line polycythemia, a previous (but unsubstantiated) diagnosis of von Willebrand's disease, glaucoma, and hypertension. Aside from multiple surgical scars, the physical examination was unremarkable; the tongue appeared normal at that time. Considering hereditary angioedema as a possible cause of the tongue swelling, a gastroenterologist had obtained C3 and C4 levels and a CHs0. The former were normal, but the CHso was immeasurably low. These tests were repeated together with other measurements noted in Table I . The most striking result was the absence of measurable hemolytic C4 activity in the presence of a normal C4 level as measured immunologically. Subsequent tests showed similar results except that hemolytic C2 was only one-fourth of control levels.
The following additional abnormalities have been noted: WBC of 13,500, with 63% lymphocytes and increased platelets; Hgb, Hct, RBC, red cell mass, and total blood volume indicative of mild polycythemia; serum protein electrophoresis showing a polyclonal increase in ~/-globulins; IgG elevated to 1750 mg/dl and IgA elevated to 524 mg/dl, with a normal IgM and IgE; IgG subclass measurements showing only IgG1 to be increased; C3b increased on immunofixation but normal alternative pathway activation following inulin stimulation; Clq binding of I4% (borderline, I3-I6%); a Raji cell test of 254 ~g AHG Eq/ml (normal, <50); and a rheumatoid factor titer of 1:20 in chilled serum and negative at 1:20 in 37°C serum.
The most relevant normal or negative tests were the urinalysis, erythrocyte sedimentation rate (3 mm/hr), C-reactive protein, antinuclear antibody, anti-DNA, hepatitis B antigens and antibodies, virus antibody screen, and cold agglutinins. In three tests there was an absence of cryoglobulin, cryofibrinogen, or heparin-precipitable cryoprotein after 7 days' observation and no decrease in C4 binding protein. Alpha-1 protease inhibitor and antithrombin III levels were normal. Tests for antimitochondrial, anti-smooth muscle, anti-parietal cell, anti-thyroglobulin, and anti-microsomal antibodies have been negative, as well as tests for von Willebrand's disease and coagulation abnormalities. Most liver function tests were normal. Subsequently a diagnosis of probable lymphocytic leukemia has been made based on persisting lymphocytosis and 5% of cells in the bone marrow appearing to be lymphoblasts. Flow cytometry in 1986 showed a T cell lymphocytosis with atypical surface phenotype. The patient has not experienced significant adverse symptoms on exposure to cold.
Patient 2
Patient 2, a 27-year-old married female, had fortuitously been found in 1984 to have an immeasurably low CHs0 level on three occasions when she served as a control for complement tests. Her antinuclear antibody test had been positive at a dilution of 1:320 (homogeneous pattern), she had been experiencing Raynaud's phenomenon for about 10 years, and during the preceding year she had a marked facial reaction to sun exposure. The medical history included recurrent urinary tract infections with pyelonephritis, recurrent staphylococcal infections including septic arthritis of the left knee, perirectal abscess, and deep venous thromboses. Physical examination was essentially within normal limits except for evidence of mitral valve prolapse. She was brought to our attention when we presented patient 1 at a local conference.
Complement measurements (Table I) More recently patient 2 has experienced recurrent arthralgias and episodes of pleuritic chest pain, and there have been two spontaneous abortions. Synovectomy of the left knee has been followed by the placement of a total knee prosthesis. Following sun exposure in 1990 she had a severe exacerbation of her disease including neurological symptoms. Exposure to cold has not produced difficulty other than Raynaud's phenomenon.
MATERIALS AND METHODS
Some blood samples were clotted for 1 hr at 4°C, centrifuged at that temperature, snap-frozen in aliquots in liquid N 2, and stored at -70°C; other blood samples were placed in tubes prewarmed to 37°C, transported to the laboratory in warmed sand at 37°C, centrifuged at 37°C, and immediately snapfrozen in aliquots; and additional blood samples were collected in tubes containing EDTA or heparin and the plasma snap-frozen in aliquots after centrifugation at 4°C. CHs0, hemolytic C4, and hemolytic C 1 were assayed according to the methods of Kabat and Mayer (15), Cooper and Muller-Eberhard (16), and Borsos and Rapp (17), respectively. Similar procedures were used in another laboratory in the tests reported in Table I . Our hemolytic C4 values are based on reciprocal serum dilutions where Z = 1 (16) . C4a and C3a were determined by radioimmunoassay using an Upjohn Co. kit, and C4d/C4 ratios were measured by rocket immunoelectrophoresis as described by Milgrom et al. (18) . Experiments involving mixtures of serum containing CDAC factor(s), or precipitates therefrom, and normal serum employed the procedure of Atkinson et al. (10) .
Clg-CI~-(C1 INH)2 Assays
Anti-Cls serum was obtained from a goat immunized with Cls purified by the method of Sim (19) , the antiserum being purified by affinity chromatography. C1 INH was purified by the method of Salvesen et al. (20) . Clg-CI~-(C1 INH)2 complexes were measured by the enzyme-linked immunosorbent assay (ELISA) procedure described by Harpel and Cooper (21) and subsequently modified according to the method of Nilsson and Back (22) . Briefly, ELISA plates were coated overnight at 4°C with 1 ixg/ml of the afffinity-purified goat anti-C 1 s or F(ab') 2 fragments therefrom. Following blocking with gelatin solution, test serum diluted in phosphatebuffered saline (PBS)-Tween with 20 mM EDTA was introduced into the wells, and after overnight incubation at 4°C Clg--CI~'-(C1 INH) 2 complexes were quantitated following sequential reactions with 2 ~g/ml mouse monoclonal anti-C1 INH, 1:5500 human adsorbed peroxidase-conjugated goat anti-mouse IgG serum (Caltag Labs, San Francisco, CA), and enzyme substrate. Control wells were coated with normal goat IgG. In agreement with Nilsson et al. (22) , it was found that in order to compare results at different serum dilutions, it is necessary to precipitate out inhibitory Clqrs complexes by the addition of polyethylene glycol (PEG) 6000 to a final concentration of 6% (w/v) before diluting the serum with EDTA-containing buffer. Resulting OD readings were compared with a linear standard curve generated by serial dilutions of PEG-precipitated normal human serum which had been activated by 1 mg/ml of heat-aggregated v-globulin and which had arbitrarily been assigned a value of 1000 units (23) . The intraassay coefficient of variation averaged -5.9%, and previous freezing and thawing of sera three times did not influence the results.
Protein G Adsorption Tests
Protein G-Sepharose was purchased from Pharmacia (Piscataway, N J). Patient or control EDTA plasma was agitated for 30 min at room temperature (RT) with a double volume of washed protein G -S e p h a r o s e beads or anti-human albuminconjugated Sepharose. CaCI2 was added to the supernatants to a concentration of 14 mM. After removing the clots, the tubes were incubated for 2.5 hr at 12°C and divided into aliquots for C4d/C4 and CIt-Clg--(C1 INH)2 tests. Controls included unadsorbed plasma.
Inhibition by Heat and Restoration with C1
A redissolved euglobulin precipitate of normal serum was the source of the C1 used in this test as well as in the hemolytic assays. Aliquots of patient 1 serum obtained at 37°C were refrozen at once or were incubated for 2 hr at 4°C before refreezing. Other aliquots were heated at 56°C for 15 min before being either immediately refrozen, incubated for 2 hr at 4°C, incubated for 2 hr at 4°C following the addition of C1, or incubated for 2 hr at 4°C after the addition of C1 which had previously been heated at 56°C for 30 min. The C1 was dissolved in PBS containing 0.15 mM CaCI2, and either this or buffer alone was added to 3 vol of serum in all aliquots. The final concentration of reconstituted C I approximated that of normal serum. The various aliquots were subdivided for subsequent testing for C4d/C4 ratio, Clg-CI~-(CI INH) 2 content and hemolytic C4.
R E S U L T S
Recognition of CDAC
Attention initially was focused on the striking discrepancy between patient l's total absence of C4 hemolytic activity and the presence of normal C4 levels as measured immunologically. Considering the possibility of an unusual C4 abnormality (e.g., abnormally glycosylated or incompletely processed pro-C4), sera from eight family members were tested for CHs0, hemolytic C4, and C4 antigen, but all were normal. Activation of the classical pathway would be the most obvious possibility, but lack of clinical evidence for immune complex disease, normal ESR, absence of precipitable cryoproteins, normal levels of Clq, C4, and C3 antigen, nearly normal levels of hemolytic C2, and exclusion of C1 inhibitor deficiency at first detracted from this consideration. However, measurement of C4a and C3a serum levels provided striking evidence of C4 and C3 cleavage, but unlike most cases of in vivo complement activation, the total activatable C4 and C3 levels also were somewhat above normal (Table  IIA) . Although there was a substantial amount of C3a detected, the percentage C3 cleavage was lower than C4 cleavage as is common in fluid-phase classical complement pathway activation. Of even greater interest was the concomitant normal C4a level measured in EDTA plasma, and subsequently it was shown that CH50 and hemolytic C2 levels also were normal in patient l's EDTA or citrate plasma. These data suggested the diagnosis of CDAC. It resulted from the procedure at that time of sending blood for serum hemolytic complement levels to the pathology laboratory on ice, whereas in EDTA plasma C 1 activation is inhibited by the chelation of Ca 2+ by EDTA.
Testing for CDAC
In general, documenting CDAC involves demonstrating functional classical pathway activation in chilled serum but not in (a) cold EDTA plasma or (b) serum obtained from blood maintained at 37°C. The latter requires meticulous specimen collection (see Materials and Methods) but permits one to study mechanisms of CDAC by subsequent con- trolled activation in the cold. As in some previously reported cases, our attention was directed to a complement abnormality by finding an unexpectedly low CHso level, and subsequent CHso measurements in warm and chilled serum and in EDTA plasma yielded a pattern typical for CDAC. The CHso levels in chilled serum from patient 1 all were <22 u (N = 6), 37°C serum levels were 110 -13 u (N = 7), and EDTA plasma levels were 78 and 105 u. However, other methods of measuring complement activation provide more incisive evidence of classical pathway activation, greater sensitivity, or more convenience. Figure 1 shows measurements of CDAC activity in freshly thawed serum from patient 1 obtained on 12.8-86 before and after incubation for 4 hr at 24, 13, or 4°C. Measurements were performed by rocket immunoelectrophoresis (IEP) for C4d generation, hemolytic C4 titration, and CI~-CI~-(C1 INH) 2 complex testing. Quantitation of IEP results was achieved by measuring planimetrically the area encompassed by the upper C4d rocket and the area of the more sharply delineated C4 rocket; normally the C4d/C4 ratio is <1.2 (18) . For comparison with the other data, the hemolytic C4 titers are expressed as a percentage of the unincubated specimen value. Figure 2 shows similar evidence for CDAC activity as assessed by these three tests in serum obtained on 4-12-88; additional tests yielded the same results on serum obtained on 4-4-90. The finding of greater CDAC activity at 13 than at 4°C was confirmed in five additional experiments including three using patient 2 serum. Earlier observations employing CHs0 measurements of serum from patient 1 showed no evidence of CDAC at 32 or 29°C, but beginning complement activation was observed at 26°C. Serum obtained from patient I at 37°C required chilling for 3 hr at 4°C to achieve maximal complement activation. As shown in Table IIB that the C4d/C4 ratio in column 3 exceeds the average of columns 1 and 2 also supports this conclusion. Similar results were obtained in six other experiments.
Assessing the Mechanisms of CDAC
Supporting previous data suggesting that the CDAC factor(s) is IgG (10), Table IV shows results representative of three experiments in which patient 1 plasma and control EDTA plasma were batched-adsorbed by protein G-Sepharose. In other experiments it was shown that more than 99% of the IgG was removed by this procedure. Results of both the C4/C4d and the Clg--CI~-(C1 INH) 2 tests indicate an accompanying marked loss in CDAC activity which was much greater than that following adsorption with anti-human serum albumin Sepharose. It was necessary to do these adsorptions in EDTA plasma (followed by recalcification) rather than in serum, because the latter procedure resulted in significant complement activation. Table V shows the results of an experiment in which patient 1 and normal sera were precipitated by 2.5% PEG in PBS with 20 mM EDTA for 2 hr at 4°C. After washing with 2.5% PEG in PBS, the precipitates were (largely) dissolved in 37°C Veronal buffer, mixed with normal serum, incubated for 22 hr at 4°C, and aliquoted for C4d/C4, CI~CI~-(CI INH)2, and hemolytic C4 assays. As shown in Table V , results from all three tests showed substantial complement activation at 4°C after mixing the redissolved PEG precipitate from patient 1 with normal serum, whereas the PEG precipitate from normal serum (B.Z.) did not have this effect. This indicates that the CDAC factor(s) is included among the substances precipitated by 2.5% PEG. In view of the significantly low levels of hemolytic C4 in our patients' sera and the variable and sometimes almost-normal levels of hemolytic C2 and C1, consideration was given to the possible presence of a cold-reactive autoantibody to C4 causing secondary activation of the classical pathway. This was explored by a series of more than 30 ELISA tests using wells coated with human C4 or with goat anti-human C4, the latter being employed to test for possible IgG:C4 complexes. Patient 1 serum usually gave higher OD readings than control sera, but it also gave higher OD measurements in wells coated with various heterologous materials: specific autoantibodies to C4 could not be demonstrated.
Considering the possibility that CDAC might have a direct effect on C4 other than through an autoantibody mechanism, the effect of heating patient 1 serum at 56°C for 15 min was examined. As expected, heating per se caused some C4 cleavage and loss of C4 hemolytic activity in addition to loss of CDAC (Table VI) , but CDAC activity was restored by the addition of C1 but not by heat inactivated C1. This requirement for C1, which was reproduced in another experiment, is characteristic for classical complement pathway activation and opposes a direct effect of CDAC factor(s) on C4 or C4 binding protein.
Effect of a CDAC Factor(s) on Other Tests
Since CDAC factor(s) may be a form of aggregated IgG, patient 1 serum obtained at 37°C was incubated for 3 or 5 hr at either 4 or 37°(2, and the effect on Raji cell tests was noted. The positive results, averaging 197 p.g AHG Eq/ml (normal, <50 AHG Eq/ml), were essentially the same after incubation at either temperature. Likewise chilling the serum for 3 or 5 hr at 4°C did not change the borderline results of patient l's CIq binding assay.
Since FACS analyses involve incubating cells in the cold and about 26% of patient l's lymphoid cells did not demonstrate the usual markers, the effect of incubating normal peripheral WBC with her heparinized plasma for 1.5 hr at 4°C was determined to see if her plasma might interfere with this test. However, there was no change in the percentage of cells expressing CD3, CD4, CD8, or CD19 markers as compared with unincubated cells or cells incubated with normal plasma.
DISCUSSION
Since CDAC is an in vitro phenomenon, afflicted individuals do not experience difficulty upon exposure to cold as in some other immune cryopathies such as cryoglobulinemia, cryofibrinogenemia, cold urticaria, or cold hemolysin syndrome. CDAC also clearly differs in mechanism from cases of coldpromoted activation (CPA) of blood coagulation factor VII (24) mediated through contact system activation and from cold-dependent consumption of C3 (25) mediated through the alternative complement pathway. Hishitani et al. (26) have reported that the occurrence of a CDAC-type phenomenon in patients with liver disease often is associated with precipitable mixed cryoglobulins. However, centrifugation of serum from our patients I and 2 after 7 days at 4°C repeatedly yielded no visible precipitate, and others have failed to find cryoprecipitates in cases not associated with liver disease. Another difference between CDAC and some cases of cryoglobulinemia is a decreased level of Clq and C4 antigen in the latter (27) , whereas the lack of immune complex sequestration in vitro results in normal values in CDAC even though split products can be detected and hemolytic activity is compromised. Thus, in accord with most other investigators, we have used the term CDAC in a more restricted sense which excludes cryoglobulinemia and the cold hemolysin syndrome. Perhaps a better term would be "idiopathic cold-dependent activation of complement." CDAC was initially recognized by discrepant CH50 and hemolytic C4 values between serum obtained at 4°C and those measured in EDTA plasma. Here it has been shown that measurements of C4d/C4 ratios, C4a, C3a, and CIg--CI~-(CI INH) 2 complexes also can be used to document CDAC and that results obtained by these various methods parallel each other. No doubt other tests of classical complement pathway activation also could be utilized. The choice of which procedure to use therefore becomes largely a matter of convenience, rocket immunoelectrophoresis for C4d/C4 ratios and CHso measurements being relatively simple. Hemolytic C4 measurements clearly provide the greatest sensitivity, but for some research purposes this can be disadvantageous; e.g., some lots of serum already had low hemolytic C4 values when blood supposedly obtained and processed at 370(2 was not meticulously handled, and in some instances there was so much loss of hemolytic C4 activity at 4°C that it was difficult to appreciate the difference from results at 13°C that were more easily recognized by other methods (Fig. 2) . This may be one reason why previous investigators have not noted that the optimal temperature for CDAC may be between 4°C and room temperature. Possibly more of the factor(s) responsible for CDAC aggregates at the lower temperature (i.e., 4°C), but consequent complement activation is enhanced at a higher temperature (e.g., 13°C). The data indicating complement activation when normal serum is mixed with CDAC serum at 4°(2 (Table III) (10) . The opportunity to test serum from patient 1 over a period of more than 5 years establishes that CDAC may be more than a transient phenomenon.
Our observation that CDAC activity is reduced by adsorption with streptococcal protein G-Sepharose (Table IV ) supports the conclusion of Atkinson et al. (10) that it is IgG based on partial purification by ammonium sulfate precipitation at 4°C followed by DEAE column chromatography at room temperature. The additional observation that CDAC activity is precipitated by 2.5% PEG strongly implies that polymeric IgG is involved, since monomeric IgG would not be expected to precipitate significantly at this PEG concentration (28) . The presence of CDAC activity in 2.5% PEG precipitates, as shown by mixing with normal serum (Table V) , augments the finding of Takemura et al. (12) that such precipitates are anticomplementary. In interpreting these results it should be noted that, in addition to precipitating proteins, PEG has been reported to enhance the aggregation of IgG by IgM rheumatoid factor (29) . Hishitani et al. (26) reported that the precipitable cryoglobulin in their (mainly) liver disease patients which produced features of CDAC was a mixed cryoglobulin consisting of IgM and polyclonal IgG. Patient 1 serum, however, had only minimal rheumatoid factor activity, and the partial purification procedure employed by Atkinson et al. (10) should largely exclude IgM. Many monoclonal IgG cryoimmunoglobulins are IgG3, but patient 1 did not have an elevated IgG3 serum level. Accordingly, one may speculate that the factor(s) responsible for CDAC in our patients, and in others without cryoprecipitates, contains polymeric IgG in a form too small or otherwise incapable of precipitating spontaneously in the cold. An alternative would be antigen-containing immune complexes of similar size and physical properties. In patient 1, however, the extensive testing noted above for antibodies to many exogenous and autologous antigens has yielded negative results. Regardless of the exact nature of the CDAC factor(s) in these patients, they appear to act through activation of the classical complement pathway. Unexpectedly high hemolytic C2 levels in relation to hemolytic C4 have also been noted in patients with hereditary angioedema (30) and might be due to reduced cleavage of C2 in the absence of C4. The cascade principle of complement activation of course would predict less evidence for C1 than C4 activation. Autoantibodies to C4 with secondary activation of the classical pathway could not be demonstrated.
